Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain.

[1]  Y. Fujiwara,et al.  Reference Values and Age Differences in Body Composition of Community-Dwelling Older Japanese Men and Women: A Pooled Analysis of Four Cohort Studies , 2015, PloS one.

[2]  W. Haefeli,et al.  Pharmacokinetic interaction of intravenous fentanyl with ketoconazole , 2015, Journal of clinical pharmacology.

[3]  Yuhong Li,et al.  Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1′-Hydroxylation , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[4]  M. Doi,et al.  Impact of CYP3A5*3 on Plasma Exposure and Urinary Excretion of Fentanyl and Norfentanyl in the Early Postsurgical Period , 2014, Therapeutic drug monitoring.

[5]  S. Kaasa,et al.  Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study , 2014, Pharmacogenetics and genomics.

[6]  H. Itoh,et al.  Association of Plasma Concentration of 4β-Hydroxycholesterol with CYP3A5 Polymorphism and Plasma Concentration of Indoxyl Sulfate in Stable Kidney Transplant Recipients , 2014, Drug Metabolism and Disposition.

[7]  Y. Yamada,et al.  Population Pharmacokinetics of Transdermal Fentanyl in Patients With Cancer-Related Pain , 2012, Journal of pain & palliative care pharmacotherapy.

[8]  L. Bertilsson,et al.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.

[9]  A. D. Rodrigues,et al.  Does the Long Plasma Half‐Life of 4β‐Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric? , 2010, Journal of clinical pharmacology.

[10]  W. Doub,et al.  Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin. , 2010, Journal of pharmaceutical sciences.

[11]  T. Bieber,et al.  4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. , 2009, International journal of clinical pharmacology and therapeutics.

[12]  E. Kalso,et al.  Transdermal fentanyl in cachectic cancer patients , 2009, PAIN®.

[13]  D. Greenblatt,et al.  Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs , 2008, Journal of clinical pharmacology.

[14]  L. Bertilsson,et al.  CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels , 2008, European Journal of Clinical Pharmacology.

[15]  L. Bertilsson,et al.  Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. , 2008, British journal of clinical pharmacology.

[16]  L. Bertilsson,et al.  4&bgr;-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians , 2008, Pharmacogenetics and genomics.

[17]  S. Clarke,et al.  Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer , 2006, Clinical Cancer Research.

[18]  E. Kharasch,et al.  Influence of Hepatic and Intestinal Cytochrome P4503A Activity on the Acute Disposition and Effects of Oral Transmucosal Fentanyl Citrate , 2004, Anesthesiology.

[19]  C. Regnard,et al.  Severe respiratory depression and sedation with transdermal fentanyl: four case studies , 2003, Palliative medicine.

[20]  I. Björkhem,et al.  Metabolism of 4β-Hydroxycholesterol in Humans* , 2002, The Journal of Biological Chemistry.

[21]  P. McNamara.  Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care , 2002, Palliative medicine.

[22]  J. Azuma,et al.  Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.

[23]  P. Neuvonen,et al.  Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. , 1999, Anesthesiology.

[24]  T. Naito,et al.  Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. , 2012, Drug metabolism and pharmacokinetics.

[25]  A. Wagstaff,et al.  Transdermal Fentanyl , 2012, Drugs.

[26]  J. Lötsch,et al.  Pharmacokinetics of Non-Intravenous Formulations of Fentanyl , 2012, Clinical Pharmacokinetics.

[27]  G. Wakabayashi,et al.  Influence of body fat in cancer patients on residual content of used fentanyl matrix patches , 2010 .

[28]  L. Bertilsson,et al.  4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. , 2009, British journal of clinical pharmacology.

[29]  K. Nakagawa,et al.  Interleukin 6 is associated with cachexia in patients with prostate cancer. , 2007, Urology.

[30]  Hartmut Derendorf,et al.  How Important Are Gender Differences in Pharmacokinetics? , 2002, Clinical pharmacokinetics.